Skip to main content
ELAB
NASDAQ Life Sciences

PMGC Holdings Reports Widening Losses, Going Concern Warning, and Heavy Dilutive Financing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.94
Mkt Cap
$4.271M
52W Low
$0.84
52W High
$309.12
52W Position info
12% above low
Off High info
100% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ELAB is trading near its 52-week low of $0.84 (12% above the low) on light trading volume (0.1× avg).

Summary

PMGC Holdings' Q2 2026 10-Q shows a $7.9M H1 net loss, a going concern warning, and $23.9M raised via dilutive ELOC facilities with conversion prices at 88-97% of VWAP.


Key Events · Earnings and Guidance · ELAB

  • Going Concern Warning Reiterated

    Management states substantial doubt about the company's ability to continue as a going concern, citing accumulated deficit of $28.9M and H1 2026 net loss of $7.9M.

  • Net Loss Widens Sharply

    H1 2026 net loss of $7,908,641 vs $2,170,810 in H1 2025, driven by higher consulting fees, office costs, and interest expense on new convertible debt.

  • Dilutive ELOC Financing

    Company raised $23.9M via two equity line of credit facilities totaling up to $60M. Conversion prices are 88% (First ELOC) and 97% (Second ELOC) of lowest VWAP, with 8.5% and 7.5% interest rates.

  • Post-Quarter Debt Settlement

    After June 30, 2026, the company issued 1,942,055 shares at $1.07-$1.10 to settle $2,114,000 of Second ELOC debt, leaving $5.85M outstanding.


Analysis · ELAB · Life Sciences

PMGC Holdings' Q2 2026 10-Q reveals a net loss of $7.9 million for the first half, more than triple the prior-year loss, while management reiterates substantial doubt about the company's ability to continue as a going concern. The company raised $23.9 million through two equity line of credit facilities with deeply discounted conversion terms, and issued 1.9 million shares after quarter-end to settle $2.1 million of that debt. The filing also discloses the acquisition of two aerospace machining businesses and a $100 million SPAC IPO filing by a 51%-owned subsidiary. The combination of accelerating cash burn, going concern language, and convertible debt with 88-97% of VWAP conversion prices creates significant dilution risk for existing shareholders.

How filings like this one have moved

In the 30 days to Nov 5, 2026, 43.3% of the 1277 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ELAB was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.84 to $309.12. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELAB - Latest Insights

ELAB
Nov 02, 2026, 4:00 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.12
Real-time Price: $1.76 info
Change: -$0.3626 (-17%) info
Market Cap: $1.423M info
ELAB
Oct 01, 2026, 8:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $3.62
Real-time Price: $1.76 info
Change: -$1.86 (-51%) info
Market Cap: $1.423M info
ELAB
Sep 18, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.70
Real-time Price: $1.76 info
Change: -$2.94 (-63%) info
Market Cap: $1.423M info
ELAB
Sep 02, 2026, 5:04 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.20
Real-time Price: $1.76 info
Change: -$3.44 (-66%) info
Market Cap: $1.423M info
ELAB
Sep 01, 2026, 7:45 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.23
Real-time Price: $1.76 info
Change: -$3.47 (-66%) info
Market Cap: $1.423M info